本帖最后由 老马 于 2013-3-13 13:43 编辑 - O- H- d6 ?. \
6 a$ `$ h# R, o d' k( q8 @, t- t9 I
健择（吉西他滨）+顺铂+阿瓦斯汀
+ @& J+ d% |+ F3 f0 B Gemzar +Cisplatin + Avastin& T& o$ ~& i" P: C: b
http://annonc.oxfordjournals.org/content/21/9/1804.full
X7 Q8 i- U' Y7 k T4 NOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 N5 T! y, l: c. Q8 G" K3 R k, v* O$ VPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 7 b& n8 X' { @5 r
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 9 t' ~! z# s* }( ~# Q5 ^4 T
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 942)
$ C* l2 m! a1 q. K5 o
华为网盘附件：
: K9 f) L, N/ t! @8 I4 a8 N【华为网盘】ava.JPG
1 Z) [( f; U) t) F( e |
显身卡
